Fawzy Basta, MD
Psychiatry · Northridge, CANPI 1043394505
Payments from drug & device makers
Across 995 payments — averaging $282.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$131K
- Acadia Pharmaceuticals Inc$77K
- Teva Pharmaceuticals USA, Inc.$49K
- AbbVie$15K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Otsuka America Pharmaceutical, Inc.$939
- plus $6K from 26 others
What the payments were for
- Consulting fees$32,30111%
- Speaking & faculty fees$216,10577%
- Travel & lodging$9,1993%
- Food & beverage$23,0408%
- Education$4710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 203 | $130,630 |
| Acadia Pharmaceuticals Inc | 104 | $76,762 |
| Teva Pharmaceuticals USA, Inc. | 163 | $49,260 |
| AbbVie(2 entities) | 129 | $15,127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $2,113 |
| Otsuka America Pharmaceutical, Inc. | 46 | $939 |
| Lundbeck LLC | 46 | $863 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $774 |
| E.r. Squibb & Sons, L.L.C. | 28 | $654 |
| Johnson & Johnson | 21 | $519 |
| Alkermes, Inc. | 23 | $484 |
| Vanda Pharmaceuticals Inc. | 16 | $428 |
| Bausch Health US, LLC | 18 | $366 |
| Avanir Pharmaceuticals, Inc. | 16 | $309 |
| Sunovion Pharmaceuticals Inc. | 27 | $272 |
| Alpha Cognition USA, Inc. | 7 | $238 |
| Corium, LLC | 10 | $200 |
| Almatica Pharma LLC | 7 | $191 |
| Merck | 7 | $170 |
| Indivior Inc. | 7 | $168 |
| Axsome Therapeutics, Inc. | 5 | $149 |
| Neuronetics, Inc. | 2 | $88 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $86 |
| Idorsia Pharmaceuticals US Inc | 4 | $82 |
| Adlon Therapeutics L.p. | 4 | $59 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $34 |
| Tris Pharma Inc | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$126,832
- NUPLAZID$74,697
- Austedo XR$26,256
- AUSTEDO$19,637
- VRAYLAR$12,480
- TRINTELLIX$1,320
- Zunveyl$416
- SPRAVATO$117
How this compares
$281,115 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 113 | $769,191 |
| Invega SustennaPaliperidone Palmitate | 96 | $351,259 |
| Austedo XrDeutetrabenazine | 25 | $172,463 |
| AustedoDeutetrabenazine | 27 | $168,670 |
| NuplazidPimavanserin Tartrate | 22 | $90,957 |
| RexultiBrexpiprazole | 49 | $57,662 |
| Chlorpromazine Hcl | 86 | $52,103 |
| Clozapine | 347 | $38,759 |
| CaplytaLumateperone Tosylate | 22 | $37,365 |
| VraylarCariprazine Hcl | 16 | $22,145 |
| Risperidone OdtRisperidone | 85 | $19,492 |
| Clozapine OdtClozapine | 22 | $16,464 |
| Haloperidol | 343 | $16,055 |
| TrintellixVortioxetine Hydrobromide | 25 | $15,959 |
| Divalproex Sodium ErDivalproex Sodium | 211 | $15,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $130,630 | $769,191113 claims |
| Johnson & JohnsonInvega Sustenna | $519 | $351,25996 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine | $49,260 | $343,40381 claims |
| Acadia Pharmaceuticals IncNuplazid | $76,762 | $90,95722 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $939 | $57,66249 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $774 | $37,36522 claims |
| AbbVieVraylar | $15,127 | $22,14516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $2,113 | $15,95925 claims |
| MerckBelsomra | $170 | $9,45829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Northridge
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.